SWOG clinical trial number
CTSU/A022101

A Pragmatic Randomized Phase III Trial Evaluating Total Ablative Therapy for Patients with Limited Metastatic Colorectal Cancer: Evaluating Radiation, Ablation, and Surgery (ERASur)

Open
Phase
Abbreviated Title
A Pragmatic Randomized Phase III Trial Evaluating Total Ablative Therapy for Patients with Limited Metastatic Colorectal Cancer: Evaluating Radiation, Ablation, and Surgery (ERASur)
Status Notes
CTSU/A022101 has been endorsed and activated by SWOG, effective 22-Aug-2022. CTSU/A022101 was activated by ALLIANCE, effective 10-Jan-2023.
Activated
01/10/2023
Participants
ALLIANCE, ECOG-ACRIN, NRG, SWOG

Research committees

Gastrointestinal Cancer

Treatment

5-Fluorouracil Irinotecan Leucovorin Calcium Oxaliplatin Bevacizumab Capecitabine Cetuximab

Other Clinical Trials

S2303
SWOG Clinical Trial Number

Randomized Phase II/III Trial of 2nd Line Nivolumab + Paclitaxel + Ramucirumab versus Paclitaxel + Ramucirumab in Patients with PD-L1 CPS >/= 1 Advanced Gastric and Esophageal Adenocarcinoma (PARAMUNE)

Research Committee(s)
Gastrointestinal Cancer
Activated
05/06/2024
Open
CTSU/A022101
SWOG Clinical Trial Number

A Pragmatic Randomized Phase III Trial Evaluating Total Ablative Therapy for Patients with Limited Metastatic Colorectal Cancer: Evaluating Radiation, Ablation, and Surgery (ERASur)

Research Committee(s)
Gastrointestinal Cancer
Activated
01/10/2023
Open
Phase
S2107
SWOG Clinical Trial Number

Randomized Phase II Trial of Encorafenib and Cetuximab with or Without Nivolumab (NSC #748726) for Patients with Previously Treated, Microsatellite Stable, BRAFV600E Metastatic and/or Unresectable Colorectal Cancer

Research Committee(s)
Gastrointestinal Cancer
Activated
06/06/2022
100% Accrual
Accrual
100%
Open
Phase